PT  - JOURNAL ARTICLE
AU  - Patrick J. Peller
AU  - Nanda Y. Khedkar
AU  - Charles J. Martinez
TI  - Breast Tumor Scintigraphy
DP  - 1996 Sep 01
TA  - Journal of Nuclear Medicine Technology
PG  - 198--203
VI  - 24
IP  - 3
4099  - http://tech.snmjournals.org/content/24/3/198.short
4100  - http://tech.snmjournals.org/content/24/3/198.full
SO  - J. Nucl. Med. Technol.1996 Sep 01; 24
AB  - Breast cancer is the most common and, probably, the most feared malignancy of American women today. Although screening with breast examination and mammography is extremely important in the early detection of breast cancer, the limited specificity of these techniques creates the need for an adjunctive diagnostic tool. Technetium-99m-sestamibi was originally developed as a myocardial perfusion agent but also preferentially accumulates intracellularly in metabolically active breast cancer tissue. Sestamibi breast imaging can delineate breast cancers and exclude the presence of a neoplastic process with high accuracy. Careful attention to imaging parameters provides high-quality breast tumor scintigraphy. Breast scintigraphy can be a valuable, adjunctive diagnostic tool in evaluating breast abnormalities.